Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients (ANTHICUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00543894
First received: October 11, 2007
Last updated: August 11, 2008
Last verified: June 2007
  Purpose

Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A prospective, observational, multicenter study (ANTHICUS).


Condition
Infection in ICU

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A Prospective, Observational, Multicenter Study (ANTHICUS)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Secondary Outcome Measures:
  • the frequency of appropriate antibiotic therapy (defined as the use of antibiotic(s) with "in vitro" efficacy against the identified pathogens responsible for the infection)
  • the frequency of "the strategy of de-escalation" according to the culture results

Enrollment: 500
Study Start Date: February 2006
  Eligibility

Criteria

Inclusion Criteria:

  • Patients with hospital-acquired infections and hospitalised in the ICU at one moment of their hospital stay
  • Hospital-acquired infections accounting for eligibility are:

    • nosocomial pneumonia (including ventilator-associated pneumonia)
    • bacteremia
    • intra-abdominal infections
    • urosepsis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00543894

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Pr Vogelaers UZ Gents
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00543894     History of Changes
Other Study ID Numbers: SRP-HB-MER-2005/1
Study First Received: October 11, 2007
Last Updated: August 11, 2008
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:
Antibiotic, ICU, hospital acquired infection.

Additional relevant MeSH terms:
Cross Infection
Infection
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents

ClinicalTrials.gov processed this record on April 15, 2014